In pathology, the protein Ki-67 is used to analyse conspicuous tissue changes. Researchers at the University of Leipzig have now discovered how the helpful protein is formed.
Compelling evidence suggests that many MS cases could be prevented by stopping EBV infection.
rFVIIIFc therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent first ITI therapy.
The final results of the phase 2 AMLSG 16-10 trial showed that younger and older patients with FLT3-ITD-mutated AML benefitted from adding midostaurin to intensive chemotherapy.
A large, population-based study showed that smouldering MM is highly prevalent in individuals of 40 years or older. Approximately 1 out of 3 patients with smouldering MM may progress towards MM.
Fitusiran prophylactic therapy reduced the annual bleeding rate (ABR) in patients with severe haemophilia A or B without inhibitors. An increase in quality of life was associated with fitusiran therapy.
Teclistamab was safe and efficacious in patients with relapsed/refractory multiple myeloma (MM). The results of the phase 1/2 MajesTEC-1 trial showed durable and deepening responses in the triple-class exposed population.
Results from the POLARIX trial suggest that Pola-R-CHP may be the preferred first-line therapy for patients with diffuse large B-cell lymphoma.
CHIP was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated haematopoietic stem cells were detected in the brains of CHIP carriers.
Therapy de-escalation in patients with ALL and a low-risk MRD profile was safe, 10-year follow-up results of the UKALL 2003 trial show.
A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia (AML).
A regimen of cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in patients with newly diagnosed AML.
A triplet combination of 5-azacitidine, venetoclax, and magrolimab displayed promising response rates in newly diagnosed older, unfit, or TP53-mutated patients with acute myeloid leukaemia (AML).
Treatment with fitusiran for prophylaxis resulted in a lower rate of bleeding events and improved health-related quality of life in patients with haemophilia A or B with inhibitors.
A JAK2V617F variant with an allele frequency of over 50% is associated with a higher risk of venous thrombosis in patients with polycythaemia vera (PV).
Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukaemia (ALL).
Combination therapy of eprenetapopt plus azacytidine showed efficacy and safety in patients with TP53-mutant myelodysplastic syndrome and oligoblastic acute myeloid leukaemia.
CPX-351 therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukaemia (AML) between 60 and 75 years of age.
The dual therapy demonstrated durable and deep responses in heavily pre-treated patients with refractory MM. The combination regimen was tolerable and did not show overlapping toxicity. It is therefore a promising option for treating patients with MM.
The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP), promising first-line treatment for patients with ITP.